breast cancer
FDA approves first diagnostic tool to target triple-negative breast cancer patients
March 11, 2019Sales and Marketing Cancer, Roche, Ventana, breast cancer, pharma
Roche’s Ventana PD-L1 Assay has become the first FDA-approved companion diagnostic for the identification of patients with triple-negative breast cancer …
Eli Lilly’s Verzenios scores NICE recommendation for advanced breast cancer
January 17, 2019Sales and Marketing Cancer, Eli Lilly, NICE, Verzenios, breast cancer, pharma
Breast cancer patients in England and Wales now have access to another treatment option, as NICE announces its recommendation of …
Breast cancer cells can be transformed into fat cells using combination therapy, study shows
January 16, 2019Research and Development Cancer, EMT, breast cancer, cells, oncology, tumours
An innovative cancer treatment can turn malignant breast cancer cells into fat cells, thus preventing the formation of metastases (the …
Pfizer’s palbociclib most commonly used breast cancer drug in clinical trials
December 11, 2018Manufacturing and Production, Sales and Marketing Cancer, breast cancer, clinical trials, global data, oncology
Pfizer’s palbociclib is the most commonly used breast cancer drug in clinical trials, according to analytics firm GlobalData. The drug, …
Galectin-3: The protein paving new treatment avenues
November 1, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Galectin-3, Galectins, breast cancer, diabetes, heart disease, pharma
Matthew Blakeley, LADI-III Beamline Scientist at Institut Laue-Langevin (ILL) and Derek Logan, Associate Professor in Structural Biology at Lund University, …
NICE rejects Elil Lilly’s Verzenio for breast cancer in draft guidance
October 19, 2018Medical Communications, Sales and Marketing Eli Lilly, NICE, UK, Verzenios, breast cancer, pharma
Eli Lilly and patients with breast cancer patients in the UK have been dealt a blow as NICE confirmed that …
FDA approves Pfizer’s Talzenna for breast cancer alongside tool to identify eligible patients
October 17, 2018Research and Development, Sales and Marketing Cancer, FDA, Pfizer, Talzenna, breast cancer, pharma
Pfizer’s Talzenna (talazoparib) has secured FDA approval, it has emerged. The poly (ADP-ribose) polymerase (PARP) inhibitor is now set to …
Roche’s Kadcyla beats Herceptin breast cancer disease recurrence and death risk
October 16, 2018Manufacturing and Production, Sales and Marketing Cancer, Kadcyla, Roche, breast cancer, pharma
Roche has unveiled new data for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) in the treatment of patients with HER2-positive early …
Lilly’s Verzenio gets first-line EU approval for HER2- advanced breast cancer
October 3, 2018Research and Development, Sales and Marketing Cancer, Eli Lilly, Verzenio, breast cancer, pharma
The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged. The therapy …
Puma Biotech’s breast cancer drug authorised by European Commission, despite prior concerns
September 5, 2018Research and Development Cancer, EU, breast cancer, ec approval, puma biotechnology
Puma Biotechnology have received European Commission marketing authorisation for Nerlynx (neratinib) despite prior concerns as to the safety and efficacy …
Novartis’ investigational combo impresses in breast cancer sub-group
August 23, 2018Research and Development Cancer, Novartis, breast cancer, fulvestrant, pharma
Novartis has revealed positive new data for its investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) combined with fulvestrant in the treatment …
Pfizer notches two EU approvals, including Herceptin biosimilar
August 1, 2018Research and Development, Sales and Marketing Cancer, EMA, EU, Genetech, Herceptin, Pfizer, Trazimera, Xeljanz, biosimilar, breast cancer, pharma
Pfizer is patting itself on the back after securing two new approvals in Europe within 24 hours: Xeljanz (tofacitinib citrate) …
Extended use of breast cancer drug tamoxifen linked to increased endometrial cancer risk
July 9, 2018Research and Development, Sales and Marketing Cancer, breast cancer, endometrial cancer, pharma, tamoxifen
New evidence published in the British Journal of Surgery has indicated a troubling link between long-term use of the breast …
Roche’s Tecentriq combo gives strong Phase 3 showing in triple negative breast cancer
July 2, 2018Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma
Roche has unveiled new Phase 3 data on its immunotherapy drug Tecentriq (atezolizumab) in combination with chemotherapy (Celgene’s Abraxane) as …
AstraZeneca chalks up double Japanese approval in lung and breast cancer
July 2, 2018Sales and Marketing AstraZeneca, Cancer, Imfinzi, NSCLD, breast cancer, lung cancer, lynparza, pharma
It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
